A Case of Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib
Lenvatinib, a tyrosine kinase inhibitor (TKI), is a stronger inhibitor of vascular endothelial growth factor receptor, fibroblast growth factor receptors 1 to 4, and platelet-derived growth factor receptor (PDGFR) than other TKIs. We herein report a 77-year-old Japanese woman who received the minimu...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2022, pp.8365-21 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 8365-21 |
| container_title | Internal Medicine |
| container_volume | |
| creator | Nakashima, Saki Sekine, Akinari Sawa, Naoki Kawamura, Yusuke Kono, Kei Kinowaki, Keiichi Kawada, Masahiro Hasegawa, Eiko Akuta, Norio Suzuki, Yoshiyuki Ohashi, Kenichi Takaichi, Kenmei Ubara, Yoshifumi Hoshino, Junichi |
| description | Lenvatinib, a tyrosine kinase inhibitor (TKI), is a stronger inhibitor of vascular endothelial growth factor receptor, fibroblast growth factor receptors 1 to 4, and platelet-derived growth factor receptor (PDGFR) than other TKIs. We herein report a 77-year-old Japanese woman who received the minimum dose of lenvatinib for treatment of hepatocellular carcinoma. Within one month of starting treatment, she developed severe proteinuria, hypertension, and renal dysfunction. A kidney biopsy showed drug-induced thrombotic microangiopathy, podocytopathy, and polar vasculosis. We also observed damage to the renal tubules, where PDGFR is located. To our knowledge, this is the first report of lenvatinib-induced damage to the renal tubules. |
| doi_str_mv | 10.2169/internalmedicine.8365-21 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_jstag</sourceid><recordid>TN_cdi_pubmed_primary_35342129</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>35342129</sourcerecordid><originalsourceid>FETCH-LOGICAL-j1029-3aa34a428442f841ff5ad0645bba0a73898639fc29747ca96c0ebafcf2ce50c73</originalsourceid><addsrcrecordid>eNpdUdtOGzEUtCpQSaG_gPwBLPi2Fz9G4VKkVCAIfV2d9R6zjhI78nqD9mf6rV1Kw0NfzkWaGZ0zQwjl7FLwQl85nzB62GyxdcZ5vKxkkWeCfyEzLpXOSiHzIzJjmleZmMoJ-db3a8ZkVWrxlZzIXCrBhZ6R33O6gB5psHTVxbBtQnKG_nQmBvCvLuwgdeMFfQxtMGM6rOBbeg1beEWaAk0d0ieczqGroRk22NM3lzr6jHuMSB9jSOj8EB385c3NkA7467G3gzfJBU_vfTsYbGkz0iX6PSTnXXNGji1sevz-r5-Sl9ub1eJHtny4u1_Ml9maM6EzCSAVKFEpJWyluLU5tKxQedMAg1JWuiqktkboUpUGdGEYNmCNFQZzZkp5Ss4_dHdDM5la76LbQhzrg1ET4NcHYN2n6e1PAMTJrw3W_ydSQ7uftGp2GN4TqgX_JJgOYo1e_gHaGZMe</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Case of Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib</title><source>PubMed Central Open Access</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>PubMed Central</source><creator>Nakashima, Saki ; Sekine, Akinari ; Sawa, Naoki ; Kawamura, Yusuke ; Kono, Kei ; Kinowaki, Keiichi ; Kawada, Masahiro ; Hasegawa, Eiko ; Akuta, Norio ; Suzuki, Yoshiyuki ; Ohashi, Kenichi ; Takaichi, Kenmei ; Ubara, Yoshifumi ; Hoshino, Junichi</creator><creatorcontrib>Nakashima, Saki ; Sekine, Akinari ; Sawa, Naoki ; Kawamura, Yusuke ; Kono, Kei ; Kinowaki, Keiichi ; Kawada, Masahiro ; Hasegawa, Eiko ; Akuta, Norio ; Suzuki, Yoshiyuki ; Ohashi, Kenichi ; Takaichi, Kenmei ; Ubara, Yoshifumi ; Hoshino, Junichi</creatorcontrib><description>Lenvatinib, a tyrosine kinase inhibitor (TKI), is a stronger inhibitor of vascular endothelial growth factor receptor, fibroblast growth factor receptors 1 to 4, and platelet-derived growth factor receptor (PDGFR) than other TKIs. We herein report a 77-year-old Japanese woman who received the minimum dose of lenvatinib for treatment of hepatocellular carcinoma. Within one month of starting treatment, she developed severe proteinuria, hypertension, and renal dysfunction. A kidney biopsy showed drug-induced thrombotic microangiopathy, podocytopathy, and polar vasculosis. We also observed damage to the renal tubules, where PDGFR is located. To our knowledge, this is the first report of lenvatinib-induced damage to the renal tubules.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.8365-21</identifier><identifier>PMID: 35342129</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>damage to the renal tubules ; lenvatinib ; podocytopathy ; thrombotic microangiopathy</subject><ispartof>Internal Medicine, 2022, pp.8365-21</ispartof><rights>2022 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,1879,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35342129$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakashima, Saki</creatorcontrib><creatorcontrib>Sekine, Akinari</creatorcontrib><creatorcontrib>Sawa, Naoki</creatorcontrib><creatorcontrib>Kawamura, Yusuke</creatorcontrib><creatorcontrib>Kono, Kei</creatorcontrib><creatorcontrib>Kinowaki, Keiichi</creatorcontrib><creatorcontrib>Kawada, Masahiro</creatorcontrib><creatorcontrib>Hasegawa, Eiko</creatorcontrib><creatorcontrib>Akuta, Norio</creatorcontrib><creatorcontrib>Suzuki, Yoshiyuki</creatorcontrib><creatorcontrib>Ohashi, Kenichi</creatorcontrib><creatorcontrib>Takaichi, Kenmei</creatorcontrib><creatorcontrib>Ubara, Yoshifumi</creatorcontrib><creatorcontrib>Hoshino, Junichi</creatorcontrib><title>A Case of Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>Lenvatinib, a tyrosine kinase inhibitor (TKI), is a stronger inhibitor of vascular endothelial growth factor receptor, fibroblast growth factor receptors 1 to 4, and platelet-derived growth factor receptor (PDGFR) than other TKIs. We herein report a 77-year-old Japanese woman who received the minimum dose of lenvatinib for treatment of hepatocellular carcinoma. Within one month of starting treatment, she developed severe proteinuria, hypertension, and renal dysfunction. A kidney biopsy showed drug-induced thrombotic microangiopathy, podocytopathy, and polar vasculosis. We also observed damage to the renal tubules, where PDGFR is located. To our knowledge, this is the first report of lenvatinib-induced damage to the renal tubules.</description><subject>damage to the renal tubules</subject><subject>lenvatinib</subject><subject>podocytopathy</subject><subject>thrombotic microangiopathy</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpdUdtOGzEUtCpQSaG_gPwBLPi2Fz9G4VKkVCAIfV2d9R6zjhI78nqD9mf6rV1Kw0NfzkWaGZ0zQwjl7FLwQl85nzB62GyxdcZ5vKxkkWeCfyEzLpXOSiHzIzJjmleZmMoJ-db3a8ZkVWrxlZzIXCrBhZ6R33O6gB5psHTVxbBtQnKG_nQmBvCvLuwgdeMFfQxtMGM6rOBbeg1beEWaAk0d0ieczqGroRk22NM3lzr6jHuMSB9jSOj8EB385c3NkA7467G3gzfJBU_vfTsYbGkz0iX6PSTnXXNGji1sevz-r5-Sl9ub1eJHtny4u1_Ml9maM6EzCSAVKFEpJWyluLU5tKxQedMAg1JWuiqktkboUpUGdGEYNmCNFQZzZkp5Ss4_dHdDM5la76LbQhzrg1ET4NcHYN2n6e1PAMTJrw3W_ydSQ7uftGp2GN4TqgX_JJgOYo1e_gHaGZMe</recordid><startdate>20220326</startdate><enddate>20220326</enddate><creator>Nakashima, Saki</creator><creator>Sekine, Akinari</creator><creator>Sawa, Naoki</creator><creator>Kawamura, Yusuke</creator><creator>Kono, Kei</creator><creator>Kinowaki, Keiichi</creator><creator>Kawada, Masahiro</creator><creator>Hasegawa, Eiko</creator><creator>Akuta, Norio</creator><creator>Suzuki, Yoshiyuki</creator><creator>Ohashi, Kenichi</creator><creator>Takaichi, Kenmei</creator><creator>Ubara, Yoshifumi</creator><creator>Hoshino, Junichi</creator><general>The Japanese Society of Internal Medicine</general><scope>NPM</scope></search><sort><creationdate>20220326</creationdate><title>A Case of Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib</title><author>Nakashima, Saki ; Sekine, Akinari ; Sawa, Naoki ; Kawamura, Yusuke ; Kono, Kei ; Kinowaki, Keiichi ; Kawada, Masahiro ; Hasegawa, Eiko ; Akuta, Norio ; Suzuki, Yoshiyuki ; Ohashi, Kenichi ; Takaichi, Kenmei ; Ubara, Yoshifumi ; Hoshino, Junichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j1029-3aa34a428442f841ff5ad0645bba0a73898639fc29747ca96c0ebafcf2ce50c73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>damage to the renal tubules</topic><topic>lenvatinib</topic><topic>podocytopathy</topic><topic>thrombotic microangiopathy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakashima, Saki</creatorcontrib><creatorcontrib>Sekine, Akinari</creatorcontrib><creatorcontrib>Sawa, Naoki</creatorcontrib><creatorcontrib>Kawamura, Yusuke</creatorcontrib><creatorcontrib>Kono, Kei</creatorcontrib><creatorcontrib>Kinowaki, Keiichi</creatorcontrib><creatorcontrib>Kawada, Masahiro</creatorcontrib><creatorcontrib>Hasegawa, Eiko</creatorcontrib><creatorcontrib>Akuta, Norio</creatorcontrib><creatorcontrib>Suzuki, Yoshiyuki</creatorcontrib><creatorcontrib>Ohashi, Kenichi</creatorcontrib><creatorcontrib>Takaichi, Kenmei</creatorcontrib><creatorcontrib>Ubara, Yoshifumi</creatorcontrib><creatorcontrib>Hoshino, Junichi</creatorcontrib><collection>PubMed</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakashima, Saki</au><au>Sekine, Akinari</au><au>Sawa, Naoki</au><au>Kawamura, Yusuke</au><au>Kono, Kei</au><au>Kinowaki, Keiichi</au><au>Kawada, Masahiro</au><au>Hasegawa, Eiko</au><au>Akuta, Norio</au><au>Suzuki, Yoshiyuki</au><au>Ohashi, Kenichi</au><au>Takaichi, Kenmei</au><au>Ubara, Yoshifumi</au><au>Hoshino, Junichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Case of Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2022-03-26</date><risdate>2022</risdate><spage>8365-21</spage><pages>8365-21-</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>Lenvatinib, a tyrosine kinase inhibitor (TKI), is a stronger inhibitor of vascular endothelial growth factor receptor, fibroblast growth factor receptors 1 to 4, and platelet-derived growth factor receptor (PDGFR) than other TKIs. We herein report a 77-year-old Japanese woman who received the minimum dose of lenvatinib for treatment of hepatocellular carcinoma. Within one month of starting treatment, she developed severe proteinuria, hypertension, and renal dysfunction. A kidney biopsy showed drug-induced thrombotic microangiopathy, podocytopathy, and polar vasculosis. We also observed damage to the renal tubules, where PDGFR is located. To our knowledge, this is the first report of lenvatinib-induced damage to the renal tubules.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>35342129</pmid><doi>10.2169/internalmedicine.8365-21</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2022, pp.8365-21 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_pubmed_primary_35342129 |
| source | PubMed Central Open Access; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; PubMed Central |
| subjects | damage to the renal tubules lenvatinib podocytopathy thrombotic microangiopathy |
| title | A Case of Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T12%3A47%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_jstag&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Case%20of%20Thrombotic%20Microangiopathy,%20Podocytopathy,%20and%20Damage%20to%20the%20Renal%20Tubules%20with%20Severe%20Proteinuria%20and%20Acute%20Renal%20Dysfunction%20Induced%20by%20Lenvatinib&rft.jtitle=Internal%20Medicine&rft.au=Nakashima,%20Saki&rft.date=2022-03-26&rft.spage=8365-21&rft.pages=8365-21-&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.8365-21&rft_dat=%3Cpubmed_jstag%3E35342129%3C/pubmed_jstag%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/35342129&rfr_iscdi=true |